1Partinen M, Hirvonen K, Jama L, et al. Open-label study of the longterm efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study) [ J]. Sleep Med ,2008, 9(5) :537-541.
3Brindani F, Vitetta F, C, emignani F. Restless legs syndrome : differential diagnosis and management with pramipexole[ J]. Clin Interv Aging, 2009,4 : 305 -313.
4Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome : diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health[J]. Sleep Med,2003,4(2) :101- 119.
5Yee B, Killick R, Wong K. Restless legs syndrome [ J ]. Aust Fam Physician,2009,38 ( 5 ) :296-300.
6Earley C J, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome [ J ]. Neurology,2000,54 ( 8 ) : 1698-1700.
7Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy [ J ]. Neurology,2004,63 ( 6 ) : 1065-1069.
8Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease [ J ]. Am J Kidney Dis, 1996,28 (3) :372-328.
9Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study [ J ]. Sleep, 2007,30 (7) :866-871.
10Tan EK, Ho SC, Eng P, et al. Restless legs symptoms in thyroid disorders [ J ]. Parkinsonism Relat Disord ,2004,10 (3) : 149-151.
5Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J]. Sleep Med, 2003, 4(2): 101-119.
6Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome[J]. Neurology, 2006, 67(6)..1 034-1 039.
7Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep:a randomized, double-blind, placebo-controlled trial[J]. Sleep Med, 2009, (8) : 874-881.
8Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study [J]. J Neurol, 2006, 253(5):601-607.
9Lemke MR, Brecht HM, Koester J, et al. Effects of the do pamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease[J]. J Neurol,2006, 253 (1) :266-270.
10Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine and placebo in patients with major depression[J]. Depress Anxiety,2000, 11(2) :58-62.
